Medicus Pharma Reports 80% ORR in Phase 2 SkinJect, Plans AI-Driven Platform
Medicus Pharma's Phase 2 SkinJect 200µg cohort achieved an 80% overall response rate at Day 57 with 73% clinical clearance and 40% histological complete response in 15 patients, positioning this dose for registrational study. The Company outlined launch of an agentic AI–driven development platform and reported $8.7M cash and $31.9M raised in 2025.
1. Phase 2 SkinJect Efficacy Data
The 15-patient 200µg cohort in the SkinJect Phase 2 study demonstrated a 73% clinical (visual) clearance rate, a 40% histological complete response rate and an 80% overall response rate at Day 57, marking the highest activity observed to date and supporting this dose as the lead regimen.
2. Agentic AI–Enabled Development Platform
Medicus Pharma detailed plans for an agentic AI–enabled platform designed to optimize clinical trial design, enable dynamic site selection and enrollment forecasting, improve patient stratification and dose optimization, and enhance capital efficiency and probability of success in future studies.
3. Strategic and Financial Positioning
CEO Dr. Raza Bokhari emphasized that the Phase 2 proof-of-concept study supports regulatory and partnership engagements, with discussions planned for refining histological endpoints at the End-of-Phase 2 meeting. CFO Carolyn Bonner reported $8.7 million in cash at year-end 2025 and $31.9 million raised during 2025, aligning capital strategy with key upcoming value inflection points.
4. Upcoming Regulatory and Clinical Milestones
Medicus Pharma is preparing for an End-of-Phase 2 meeting with regulators to discuss registrational study design, histological clearance endpoints and strategic partnerships, while exploring expansion into Gorlin Syndrome and other high-burden non-melanoma skin cancer populations.